Results 201 to 210 of about 77,084 (260)

PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer. [PDF]

J Exp Clin Cancer Res
Mei W, Zhou H, Li W, Liu Y, Tang C, Wei M, Zhou Z, Ye B, Niu H, Wang W, Yang K, Zhang Y, Huang L, Yu Y, Wen X, Ye L.   +15 more
europepmc   +1 more source

Targeting IP₆ signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance. [PDF]

Nat Commun
Lee SG, Seo Y, Jeong S, Chung Y, Kong S, Kim M, Rhlee JH, Um S, Mathew BP, Maiti S, Kuram MR, Abozeid MA, Park A, Yoo JN, Khim KW, Son K, Amarsanaa E, Kim K, Hong S, Choi J, Park IB, Lee EA, Jeon JH, Park JH, Han JS, Park CY, Kim S, Choi JH, Hong SY, Seo MD, Lee H, Lee JY, Myung K.   +32 more
europepmc   +1 more source

Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance. [PDF]

J Clin Invest
Liu D, Tao K, Xu C, Yang W, Cai C, Feng C, Xiong K, Wu S, Lin Y, Peng Z, Chi J, Pan W, Zhong Q, Liu J, Li X, Liu X, Zhou D, Ma D, Zhao GN, Xia Y, Fang Y, Gao Q.   +21 more
europepmc   +1 more source

Challenges in employing overall survival as a primary outcome in ovarian cancer studies: insights from PARP inhibitor trials. [PDF]

Front Oncol
Siegler Y, Matanes E.
europepmc   +1 more source

Clinical approaches to overcome PARP inhibitor resistance. [PDF]

Mol Cancer
Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, Guan Z, Li X, Tang H.   +8 more
europepmc   +1 more source

Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer. [PDF]

J Exp Clin Cancer Res
Formenti L, Abramo F, Dellavedova G, Dematteis V, Decio A, Grasselli C, Fabbrizio P, Brunelli L, Giavazzi R, Ghilardi C.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Vasoactivity of PARP Inhibitors

2015
PARP-inhibition has proven to be an attractive therapeutic approach in cancer whereby the effectiveness of DNA-damaging therapy can be enhanced by inhibiting the PARP-mediated DNA-repair process. Generally there is good concordance between enhanced therapeutic efficacy in vitro and that observed in vivo.
Williams, Kaye J., McCrudden, Cian M.
openaire   +2 more sources

PARP Inhibitors

Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire   +2 more sources